Communications to the Editor
J ournal of Medicinal Chemistry, 1997, Vol. 40, No. 23 3711
Padbury, G. E.; Wilson, G. J .; Shiou, L.; Zipp, G. L.; Wilkinson,
K. F.; Rush, B. D.; Ruwart, M. J .; Koeplinger, K. A.; Zhao, Z.;
Cole, S.; Zaya, R. M.; Kakuk, T. J .; J anakiraman, M. N.;
Watenpaugh, K. D. Structure-Based Design of HIV Protease
Inhibitors: Sulfonamide-Containing 5,6-Dihydro-4-hydroxy-2-
pyrones as Non-Peptidic Inhibitors. J . Med. Chem. 1996, 39,
4349-4353.
Refer en ces
(1) (a) Chrusciel, R. A.; Romines, K. R. Recent Developments in HIV
Protease Inhibitor Research. Expert Opin. Ther. Pat. 1997, 7,
111-121. (b) Havlir, D. V.; Richman, D. D. Viral Dynamics of
HIV: Implications for Drug Development and Therapeutic
Strategies. Ann. Intern. Med. 1996, 124, 984-994. (c) For
coverage in the popular media, see: Leland, J . The End of AIDS.
Newsweek 1996, Dec. 2, 65-73.
(2) (a) Deeks, S. G.; Smith, M.; Holodniy, M.; Kahn, J . O. HIV-1
Protease Inhibitors: A Review for Clinicians. J . Am. Med. Assoc.
1997, 277, 145-153. (b) Moyle, G.; Gazzard, B. Current
Knowledge and Future Prospects for the Use of HIV Protease
Inhibitors. Drugs 1996, 51, 701-712.
(3) (a) Plattner, J . J .; Norbeck, D. W. Chapter 5. Obstacles to Drug
Development from Peptide Leads. In Drug Discovery Technolo-
gies; Clark, C. R., Moos, W. H., Eds.; Ellis Horwood: Chichester,
England, 1990; pp 92-126. (b) Barry, M.; Gibbons, S.; Back,
D.; Mulcahy, F. Protease Inhibitors in Patients with HIV
Disease. Clin Pharmacokinet. 1997, 32, 194-209.
(4) (a) Mascolini, M. Protease Inhibitors and Nucleoside Combina-
tions. J . Int. Assoc. Physicians AIDS Care 1996, 4, 23-33. (b)
Waldholz, M. New Aids Treatment Raises Tough Question of
Who Will Get It. Wall Street J ournal, J uly 3 1996, 1-2. (c)
Waldman, A. When You Want to Live But Cannot Afford It.
Washington Post, April 27, 1997, C01.
(5) (a) Ridky, T.; Leis, J . Development of Drug Resistance to HIV-1
Protease Inhibitors. J . Biol. Chem. 1995, 270, 29621-29623.
(B) Erickson, J . W. The Not-so-great Escape. Nature Struct.
Biol. 1995, 2, 523-529.
(6) Tummino, P. J .; Vara Prasad, J . V. N.; Ferguson, D.; Nouhan,
C.; Graham, N.; Domagala, J . M.; Ellsworth, E.; Gajda, C.;
Hagen, S. E.; Lunney, E. A.; Para, K. S.; Tait, B. D.; Pavlovsky,
A.; Erickson, J . W.; Gracheck, S.; McQuade, T. J .; Hupe, D. J .
Discovery and Optimization of Nonpeptide HIV-1 Protease
Inhibitors. Bioorg. Med. Chem. 1996, 4, 1401-1404.
(7) (a) Romines, K. R.; Chrusciel, R. A. 4-Hydroxypyrones and
Related Templates as Nonpeptidic HIV Protease Inhibitors.
Curr. Med. Chem. 1995, 2, 825-838. (b) Thaisrivongs, S.;
Skulnik, H. I.; Turner, S. R.; Strohbach, J . W.; Tommasi, R. A.;
J ohnson, P. D.; Aristoff, P. A.; J udge, T. M.; Gammill, R. B.;
Morris, J . K.; Romines, K. R.; Chrusciel, R. A.; Hinshaw, R. R.;
Chong, K.-T.; Tarpley, W. G.; Poppe, S. M.; Slade, D. E.; Lynn,
J . C.; Horng, M.-M.; Tomich, P. K.; Seest, E. P.; Dolak, L. A.;
Howe, W. J .; Howard, G. M.; Schwende, F. J .; Toth, L. N.;
(8) Vara Prasad, J . V. N.; Para, K. S.; Lunney, E. A.; Ortwine, D.
F.; Dunbar, J . B.; Ferguson, D.; Tummino, P. J .; Hupe, D.; Tait,
B. D.; Domagala, J . M.; Humblet, C.; Bhat, T. N.; Liu, B.; Guerin,
D. M. A.; Baldwin, E. T.; Erickson, Sawyer, T. K. Novel Series
of Achiral, Low Molecular Weight, and Potent HIV-1 Protease
Inhibitors. J . Am. Chem. Soc. 1994, 116, 6989-6990.
(9) Tait, B. D.; Domagala, J . M.; Ellsworth, E. L.; Gajda, C.; Hagen,
S. E.; Hamilton, H.; Vara Prasad, J . V. N.; Ferguson, D.;
Graham, N.; Hupe, D.; Nouhan, C.; Tummino, P. J .; Humblet,
C.; Lunney, E. A.; Pavlovsky, A.; Rubin, R. J .; Baldwin, E. T.;
Bhat, T. N.; Erickson, J . W.; Gulnik, S.; Liu, B. 4-Hydroxy-5,6-
dihydropyrones. 2. Potent Non-Peptide Inhibitors of HIV Pro-
tease. J . Med. Chem. 1997, 40, 3781-3792.
(10) Ranasinghe, M. G.; Fuchs, P. L. A Facile Synthesis of Unsym-
metrical Thiosulfonates via Sulfonylation of Mercaptans. Synth.
Commun. 1988, 18, 227-232.
(11) Newman, M. S.; Karnes, H. A. The Conversion of Phenols to
Thiophenols via Dialkylthiocarbamates. J . Org. Chem. 1966,
31, 3980-3984.
(12) Experimental conditions for the enzyme assay at pH 4.7:
Tummino, P. J .; Ferguson, D.; J acobs, C. M.; Tait, B. D.; Hupe,
L.; Lunney, E.; Hupe, D. Competitive Inhibition of HIV-1
Protease by Biphenyl Carboxylic Acids. Arch. Biochem. Biophys.
1995, 316, 523-528. This procedure was modified slightly when
run at pH 6.2: the buffer was changed to 1.0 mM dithiothreitol,
80 mM MES, 160 mM NaCl, 1.0 mM EDTA, and 0.1% polyeth-
ylene glycol (MW 8000). The final concentration of HIV protease
used was 1.5 nM.
(13) Buckheit, R. W., J r.; Hollingshead, M. G.; Germany-Decker, J .;
White, L.; McMahon, J . B.; Allen, L. B.; Ross, L. J .; Decker, W.
D.; Westbrook, L.; Shannon, W. M.; Weislow, O.; Bader, J . P.;
Boyd, M. R. Thiazolobenzimidazole: Biological and Biochemical
Anti-retroviral Activity of a New Nonnucleoside Reverse Tran-
scriptase Inhibitor. Antiviral Res. 1993, 21, 247-265.
J M970522Y